Beam Therapeutics Inc. (BEAM) FinancialsBEAMBeam Therapeutics Inc.

Evaluating the bottom line, Beam Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25827.14%, while the net margin is -25036.33%. These profitability ratios, combined with a Return on Equity (ROE) of -8.18%, provide a clear picture of how effectively BEAM converts its operational activities into shareholder value.

In the context of the broader market, BEAM competes directly with industry leaders such as ADMA and MBX. With a market capitalization of $2.44B, it holds a significant position in the sector. When comparing efficiency, BEAM's gross margin of 100.00% stands against ADMA's 69.31% and MBX's N/A. Such benchmarking helps identify whether Beam Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Beam's revenue showed a significant spike in Q4 2025 at $114.1 million, but it has been inconsistent, with Q2 2026 revenue dropping to $490,000. The company has a gross margin of 100%, but net income remains negative across recent quarters, indicating financial instability.